A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Class A shares of the Alger Focus Equity Fund outperformed the Russell 1000 Growth Index during the fourth quarter of 2024.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Class A shares of the Alger Spectra Fund outperformed the Russell 3000 Growth Index during the fourth quarter of 2024. Read ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Ongoing trials of the next generation of weight loss drugs are revealing something unexpected: Some patients are losing too ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...